357 results about "Purine" patented technology

The invention relates to the technical field of agricultural science, and discloses a low-purine ecological pig circulating breeding system which comprises a breeding environment regulation and control module, a low-purine feed management module, an excrement treatment module, a recycling module, a health monitoring module, an intelligent decision-making module, a traceability management module, a water quality purification module and an energy recovery module. The breeding environment regulation and control module monitors in real time and automatically regulates pig house environment parameters through a distributed sensor network; the low-purine feed management module generates a low-purine feed formula based on growth stage recognition and nutritional requirement analysis; the excrement treatment module is used for converting breeding wastes into organic fertilizer raw materials; the cyclic utilization module realizes precise returning of the organic fertilizer to the field according to planting requirements; the health monitoring module evaluates the purine level of the swinery; the intelligent decision-making module integrates the multi-source data to generate a comprehensive optimization scheme; and the traceability management module records whole-process data through a block chain technology. The stability of low-purine culture is guaranteed, and the success rate of low-purine culture is increased.

The invention provides a perovskite solar cell, a preparation method thereof and a photovoltaic module. The perovskite solar cell comprises a first electrode, a hole transport layer, a perovskite layer, an electron transport layer and a second electrode which are stacked in sequence. The material of the hole transport layer comprises a biomolecular material which is fixed on a self-assembly monomolecular layer material through an intermolecular force, and the biomolecular material comprises one or more of guanine, adenine, thymine, uracil, cytosine, hydroxymethylcytosine, xanthine, hypoxanthine, 6-mercaptopurine and corrin. According to the perovskite cell provided by the invention, the biomolecular material with a plurality of nitrogen heterocyclic structures and amino groups is added to generate multipoint hydrogen-bond interaction and pi-pi accumulation with the tail end of the SAM, so that the orderliness of molecular arrangement is improved, and the dipole direction and strength of the whole interface are regulated and controlled; and a coordination bond or hydrogen bond network is formed by the coordination compound and uncoordinated cations or anions in perovskite, so that interface defects are effectively passivated, and the thermal stability and the humid and hot life of a device are enhanced.

The invention relates to application of plant lactobacillus FBL002 in degradation of purine nucleoside, and belongs to the technical field of microorganisms. The plant lactobacillus FBL002 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on March 13, 2025, and the preservation number is GDMCC No.66015. The strain is separated from healthy infant intestinal flora, and can effectively degrade various purine nucleosides including inosine, guanosine, adenosine, guanine and adenine, so that the plant lactobacillus FBL002 is used for developing products for degrading purine nucleosides. In addition, the strain is also suitable for preparing oral hyperuricemia treatment medicines, and the contents of uric acid, xanthine oxidase and adenosine deaminase in serum can be remarkably reduced. The invention provides a safe and efficient method for managing purine metabolism abnormality related diseases by utilizing the biodegradation activity of the plant lactobacillus FBL002, and is particularly suitable for preventing and treating hyperuricemia.

The invention relates to the fields of biology, medicine and clinic. In particular to application of PAICS as a target spot in developing or screening reagents for preventing and / or treating orthopoxvirus infection, and application of inhibiting a synthetic pathway of purine nucleotide and / or inhibiting a metabolic pathway of folic acid in preparing reagents for treating and / or preventing orthopoxvirus infection diseases. In order to restrain the infection of orthopoxvirus, the inventor team uses a CRISPR / Cas9 technology to carry out generic genome screening on host cells infected by orthopoxvirus, determines a host-dependent gene PAICS gene in the orthopoxvirus infection process, and verifies and clarifies the virus-dependent mechanism of the gene; in order to deal with the global continuous orthopoxvirus infection problem, the invention plays an important role in the development and screening of future related prevention or treatment drugs, and also expands the new clinical application of existing drugs including methotrexate, mercaptopurine, mizoribine and the like.

The invention belongs to the technical field of sensors, and relates to an array sensor based on cerium-based metal organic framework nano-enzyme and detection application of perfluoroalkyl compounds. The array sensor is a Ce-MOF triple enzyme activity array sensor and is provided with a plurality of mutually independent sensing channels; the sensing channel contains a Ce-MOF nano enzyme and a chromogenic substrate; the chromogenic substrates comprise a first chromogenic substrate, a second chromogenic substrate and a third chromogenic substrate, the first chromogenic substrate comprises 3, 3 ', 5, 5'-tetramethyl benzidine, the second chromogenic substrate comprises 2, 4-diaminophenol and 4-aminoantipyrine, and the third chromogenic substrate comprises xanthine, purine oxidase and nitrogen blue tetrazole. The MOF nano-enzyme array sensor constructed by the invention has relatively high sensitivity and selectivity in identification and distinguishing of PFASs compounds, not only can accurately distinguish single PFASs compounds, but also can perform quantitative detection, and has good response to PFASs with different concentrations.

The invention discloses targeted prebiotic plant extraction dietary powder for relieving hyperuricemia and a preparation technology of the targeted prebiotic plant extraction dietary powder, and belongs to the technical field of dietary powder.In a formula of the targeted prebiotic plant extraction dietary powder for relieving hyperuricemia, as a patented bacterial strain, the bacillus coagulans MKSWC01 can directly act on the intestinal tract environment, uric acid precursor substances generated by purine metabolism are degraded in a targeted mode, and generation of uric acid is reduced from the source; the chicory root superfine powder and the mulberry leaf DNJ extract respectively activate kidney excretion protein, inhibit the activity of glycosidase, accelerate discharge of uric acid through urine and block the path of conversion from fructose metabolism to uric acid; the celery seed flavone and the smilax glabra polysaccharide further play an anti-inflammatory role, the deposition risk of urate crystals at joints is reduced, and potential inflammatory response caused by hyperuricemia is relieved. Meanwhile, the resistant dextrin and the xylooligosaccharide serve as prebiotics, nutrients are provided for probiotics to support planting of the probiotics, the overall metabolic environment can be improved by adjusting intestinal flora balance, the pathological link of hyperuricemia is comprehensively covered, and the relieving effect is improved.

The purpose of the present invention is to provide a novel beer-flavored fermented beverage in which the purine concentration is reduced and the deterioration in flavor due to the reduction in purine concentration is improved. The present invention provides a beer-flavored fermented beverage having a purine concentration of 35,000 ppb or less, an adenosine concentration of 15,000 ppb or less, or a guanosine concentration of 56,000 ppb or less, wherein the 5-methylfurfural concentration is 10 ppb or more.

The present invention provides a method for producing ribose-1-phosphate that is simple and yields improved efficiency. [Solution] A method for producing ribose-1-phosphate, comprising a contact step to produce ribose-1-phosphate and hypoxanthine by contacting inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium in a reaction solution containing inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium, wherein in the contact step, the hypoxanthine is present in an amount exceeding the saturation concentration relative to the medium.

The present application relates to a kind of purine derivatives as the use of NSD2 and NSD3 inhibitor, the structural formula of the derivative is as shown in formula (I) or formula (II).The compound shows good NSD2, NSD3 inhibitory activity, can effectively reduce the methylation level of H3K36 in cell, and cause the reduction of cell proliferation activity of NSD2, NSD3 high expression tumor cell strain.

The invention provides deuterium-enriched piperidinyl-methyl-purine amines and related compounds, pharmaceutical compositions, their use for inhibiting NSD2, and their use in the treatment of a disease or condition, such as cancer.

The invention relates to lactobacillus mucilaginosus and application thereof in fermented soybean milk. The lactobacillus mucus is preserved in the Guangdong Microbial Culture Collection Center on March 10, 2025, and the preservation number is GDMCC (China General Microbiological Culture Collection Center) No. 65866. The viable count of the fermented lactobacillus mucus in soybean milk is increased by 56%, meanwhile, the activity of beta-glucosidase is remarkably improved to 198 U / mL, and the degradation rate of total purine in soybean milk is 65.32%. In fermentation application, the total polyphenol content and the total flavone content in fermented soybean milk after fermentation are respectively increased by 39.56% and 52.32% compared with those in an unfermented system, the daidzein content and the genistein content in the fermented soybean milk after fermentation are respectively increased by 256.3% and 356.3% compared with those in the unfermented system, and meanwhile, the antioxidant activity ABTS free radical scavenging rate and the antioxidant activity DPPH scavenging rate are obviously increased to 89.6% and 94.8% respectively. The strain shows important application value in the fields of functional food development and natural cosmetic raw material production, and an innovative solution is provided for high-value utilization of plant resources.

The invention provides deuterium-enriched piperidinyl-methyl-purine amines and related compounds, pharmaceutical compositions, their use for inhibiting NSD2, and their use in the treatment of a disease or condition, such as cancer.

The invention provides application of a roxburgh rose extract in preparation of a product for treating hyperuricemia and regulation and control of a purine metabolic pathway, and belongs to the technical field of biological medicines. The roxburgh rose aqueous extract extracted from roxburgh rose pomace can effectively intervene in hyperuricemia through a dual action mechanism: on one hand, the roxburgh rose aqueous extract significantly inhibits the expression of xanthine oxidase (XOD) in the liver, and reduces the generation of uric acid; on the other hand, expression of key urate transporters (including GLUT9, URAT1, ABCG2 and OAT1) is regulated and controlled, uric acid is promoted to be excreted through the kidney, and therefore the blood uric acid level is reduced in a synergistic mode, a solid theoretical basis and technical support are provided for developing a new HUA prevention and treatment strategy based on natural products, and a new thought is provided for prevention and treatment of hyperuricemia.

The invention discloses a construction and verification method of an HEK293T cell line capable of stably overexpressing human ANT2, which comprises the following steps: cloning a human ANT2 gene, constructing the human ANT2 gene into a lentivirus expression plasmid pLVX-TRE3G, co-transfecting the lentivirus expression plasmid pLVX-TRE3G and a helper plasmid pLVX-Tet3G into an HEK293T-ACE2 cell, and carrying out puromycin and G418 pressurized screening and Western blot identification to obtain the HEK293T cell line capable of stably overexpressing human ANT2. A result shows that the expression quantity of the ANT2 is the highest when the HEK293T-ACE2-ANT2 cell is induced for 12 hours at the Doxycycline of 6mg / L; when the ANT2 is induced to express, the virus nucleic acid load and the N protein expression level after SARS-CoV-2 infection are obviously reduced, which indicates that the ANT2 has an inhibition effect on SARS-CoV-2 infection replication, and a cell model and an experimental basis are provided for exploring the effect of the ANT2 in virus infection resistance.

Novel and known substituted purine compounds and salts thereof act as adenosine A2a receptor (A2aR) antagonists for cancer immunotherapy, depression, anxiety, multiple sclerosis, NASH, scleroderma, ADHD, Alzheimer's and Parkinsons. Pharmaceutical compositions comprising such compounds, and methods of their use in treating depression are also taught.

This invention provides deuterium-enriched piperidinyl methylpurine amine salts, crystalline forms, pharmaceutical compositions, their use in inhibiting NSD2, and their use in treating diseases or ailments, such as cancer.

The invention discloses a method for improving the biomass and flavone content of a saussurea involucrata cell culture, which comprises the following steps of: culturing yellow-white saussurea involucrata callus on a culture medium at the temperature of 24 DEG C, illuminating for 16 hours / day, subculturing once every 15 days and subculturing for three times to obtain yellow-white or yellow-green callus which grows vigorously and is compact in structure; the preparation method of the culture medium comprises the following steps: weighing MS, cane sugar, naphthylacetic acid, 6-benzyladenine, coconut extract and agar in a container, adding distilled water, fully stirring, fixing the volume to 1 L, uniformly stirring, and adjusting the pH value to obtain a basic culture solution; carrying out high-pressure sterilization on the basic culture solution, pouring a flat plate, and cooling to obtain a culture medium; wherein the coconut extract is one or two of coconut water or coconut milk. By adding coconut water or coconut milk, the biomass of the saussurea involucrata callus can be remarkably increased in cooperation with the MS culture medium, and compared with an existing report, the increasing multiple is 2-3 times that of the existing report.

The invention belongs to the technical field of protein beverage processing and utilization, and particularly relates to soybean milk powder based on a white kidney bean extract and a preparation method of the soybean milk powder. The soybean milk powder is prepared by taking soybeans as a main raw material, the soybeans are subjected to peeling treatment, mechanical impurities, dust and soybean germs in the soybeans as well as purine, alkali and other components which are contained in peels and are harmful to a human body are removed, the content of bacteria is reduced, and the flavor of the soybean milk powder is optimized; the white kidney bean extract is added, and the white kidney bean extract contains an alpha-amylase inhibitor which can inhibit the activity of alpha-amylase, so that absorption of carbohydrates is delayed and partially blocked, the blood sugar level is favorably controlled, rapid increase of postprandial blood sugar is reduced, and the anti-saccharification effect is indirectly achieved; meanwhile, the white kidney bean extract is rich in high-quality protein, various amino acids, mineral substances, vitamins B1 and B2 and the like, so that the health level of a human body can be further improved.

2'-Fluoro-6'-methylene-carbocyclic adenosine (FMCA, 21) and its phosphoramidate prodrug (FMCAP, 31) have demonstrated potential anti-HBV activity against both adefovir- resistant as well as lamivudine-resistant double (rtL180M / rtM204V) mutant hepatitis B virus (HBV). In addition, in vitro, these molecules have reinstated a significant activity against lamivudine / entecavir triple mutants (L180M+S202G+M204V). This invention is directed to compounds, pharmaceuticals and methods of treating HBV infections, especially including infections caused by resistant and multiple resistant HBV. Pursuant to the present invention, a complete structure-activity relationship (SAR) of 2'-fluoro-6'-methylene-carbocyclic derived nucleos(t)ides has been evaluated and that analysis is presented herein. Pursuant to the present invention, the synthesis and antiviral evaluation of purine and pyrimidine-derived nucleosides have been reported against wild-type and various HBV mutants. Guanosine analog (FMCG, 25) demonstrated an EC50 value of 0.217μM and cytosine analog (FMCC, 41) expressed a potent EC50 value of 0.0025 μM compared to entecavir (EC50 = 0.0029) against wild-type HBV. Additionally, FMCC (41) maintains its antiviral potency against various HBV mutants. Furthermore, chiral pure FMCAP Sp (34) isomer demonstrated an EC50 value of 1.3 nM and was more potent against several HBV mutants than entecavir.

To provide a beer-flavored beverage having an excellent taste and little astringency, while having a reduced content of purines. [Solution] A beer-flavored beverage having a purine content of 15 ppm or less and a peptide content of 35 to 50 kDa molecular weight of 1.5 to 50 ppm.

The invention discloses an NLRP3 inhibitor as well as a preparation method and application thereof. Specifically, the invention relates to a compound shown as a formula (NLRP3i-3) or a pharmaceutically acceptable salt thereof, the formula (I) is COCCNc1nc2c (c (= O) n (C) c (= O) n2C) n1Cc1cc (OC) ccc1N, and the chemical name is 8-((4-amino-2-methoxybenzyl)-7, 9-dimethyl-7, 9-dihydro-8H-purine-6, 8-diketone. The invention also provides a preparation method of the compound, a pharmaceutical composition containing the compound, and application of the compound in preparation of drugs for preventing and / or treating NLRP3-mediated diseases. The disease is preferably myocardial ischemia reperfusion injury. Experimental results show that the compound provided by the invention has excellent NLRP3 inhibitory activity (IC50lt, 100nM), and has high selectivity to NLRP3 inflammasomes; good pharmacokinetic characteristics are achieved in a rat body, and the bioavailability is high; in myocardial ischemia reperfusion injury models of mice and rats, the composition can significantly reduce myocardial infarction area, reduce myocardial enzyme level, alleviate inflammatory response and improve heart function; preliminary toxicological evaluation shows that the safety is good. Therefore, the compound disclosed by the invention is expected to be developed into a novel medicine for treating NLRP3 related diseases such as myocardial ischemia-reperfusion injury.

The present invention relates to a novel purine derivative compound and a composition for enhancing an immune response comprising same as an active ingredient. The compound of the present invention not only has a nanomolar EC50 value for TLR7, which is an intracellular membrane receptor of immune cells, but also has high selectivity for TLR7 compared to TLR8, which has a similar structure and is mainly distributed in the endoplasmic reticulum (ER), thereby being able to induce sustained immune activation. Therefore, the compound of the present invention can be effectively used as an efficient vaccine adjuvant composition against various RNA viruses including influenza virus, SARS-CoV-2, and hepatitis C virus.

The invention discloses a method for reducing the purine content of phaseolus calcaratus powder, and belongs to the technical field of edible bean processing. The method comprises the processes of acid-assisted hydrothermal treatment and isoelectric precipitation. The acid-assisted hydrothermal process comprises the following steps: mixing 0.1-1 mol / L of hydrochloric acid, 0.5-1 mol / L of phosphoric acid or 0.8-1 mol / L of citric acid with the phaseolus calcaratus powder, and stirring and heating at 60-70 DEG C; and the isoelectric precipitation is to precipitate and recover the phaseolus calcaratus protein under the condition that the pH value of the mixed system is 3-5. And freeze-drying the precipitate, and grinding to obtain the low-purine phaseolus calcaratus powder. The processing conditions can effectively reduce the purine content in the phaseolus calcaratus, so that the processing loss can be effectively controlled, and the higher protein content can be kept; the problem that the purine content in phaseolus calcaratus is high at present can be solved, and a new method is provided for research and development of low-purine phaseolus calcaratus products.

This invention provides an induction culture medium and method for using marigold anthers as explants. The induction culture medium is based on MS solid medium containing agar, with specific amounts of sucrose, tryptophan, phenylalanine, arginine, casein amino acids, anhydrous asparagine, 6-benzylpurine, naphthaleneacetic acid, silver nitrate, pyridoxine hydrochloride, thiamine hydrochloride, nicotinic acid, D-biotin, folic acid, ascorbic acid, and coconut juice added. This invention also provides a method for induction culture using this induction culture medium. This invention can greatly improve the callus induction rate of marigolds, significantly increasing the number of regenerated seedlings, and provides technical guidance for the cultivation of haploid marigolds using anthers.

The present disclosure relates to filters configured for a spectroscopic antibiotic susceptibility analysis and a method for filtering a sample for a spectroscopic antibiotic susceptibility analysis. In one example, a method comprises providing a solution comprising bacteria incubated in a media to a well, filtering the solution via adsorption to trap at least a portion of the bacteria in a filter separate from the media. providing a solution of SERS active nanoparticles to the well, and spectroscopically analyzing the filter to determine the presence and / or absence of at least one of a purine and a pyrimidine. Methods of providing an internal standard in a spectroscopic antibiotic susceptibility test are also provided.

Methods of treating, reducing the risk of, preventing, or alleviating a symptom of inflammation or inflammatory gastrointestinal disease by administration of a modified bacterium providing purines, in particular hypoxanthine, to the mucosa of the intestine, and compositions containing modified bacteria useful in such methods.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazo-pyridine structure, or compounds having a pyridinyl-purine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and are useful as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes (e.g., any type or form of diabetes, including type-1 or type-2), autoimmune diseases, inflammatory disorders (e.g., airway inflammation), cancer (e.g., glioblastoma, prostate cancer), diabetes, and other diseases.

The purpose of the present invention is to provide a novel beer-taste fermented alcoholic beverage in which, despite the purine concentration being reduced, deterioration of flavor and aroma, reduction in crispness of bitterness, and intensity of astringency resulting from the reduction in purine concentration are ameliorated. The present invention provides a beer-taste fermented alcoholic beverage having a purine concentration of 35,000 ppb or lower, wherein the iron concentration is 0.02 ppm or greater, and the furfuryl acetate concentration is 3 ppb or greater. According to the present invention, it is possible to provide a beer-taste fermented alcoholic beverage in which the purine concentration is reduced, wherein, despite the purine concentration being reduced, the flavor and aroma are excellent, and crispness of bitterness and intensity of astringency are improved, due to the iron concentration being set to a prescribed value.

This application discloses a purino[1,2-a]carbazolin derivative, its preparation method, and its application. Specifically, it discloses a compound having the structure shown in Formula I, or its stereoisomers, solvates, metabolites, pharmaceutically acceptable salts, cocrystals, or prodrugs: ; wherein R1 and R2 are each independently selected from hydrogen, hydroxyl, carboxyl, substituted or unsubstituted C1-C6 alkyl, -CONH-R3, and -COO-R4; wherein R3 is a substituted or unsubstituted C1-C5 alkyl, and the substituent can be any of cyano, halogen, alkylC1-C5 alkoxy, C1-C5 alkylsulfonyl, di(C1-C5 alkyl)amino, nitrogen-containing heterocyclic, aryl, and C1-C5 heteroaryl; R4 is selected from any of substituted or unsubstituted aryl C1-C5 alkyl and nitrogen-containing saturated heterocyclic C1-C5 alkyl. This compound can be used as a TDP1 inhibitor for antitumor therapy.

The present application provides: a phosphoribosylaminoimidazole-succinoylcarboxamide synthase variant; a microorganism comprising the variant; a composition for producing a purine nucleotide, the composition comprising the microorganism; and a method of producing a purine nucleotide, the method comprising the step of culturing the microorganism.